05/05/2021 | Press release | Distributed by Public on 05/05/2021 00:16 Kuur Therapeutics Ltd - Athenex to Acquire Kuur Therapeutics to expand cell therapy development with off-the-shelf engineered CAR-NKT platform Transformative, leading allogeneic NKT cell platform technology expands Athenex's cell therapy development capability Platform has broad applications based on transducing NKT cells with chimeric antigen receptors (CARs) and T cell receptors (TCRs) to target hematological and solid cancers, respectively Total potential consideration of $185 million, comprising $70 million upfront primarily in Athenex common stock, and $115 million in development milestones Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, led by its Orascovery platform, today announced that it has acquired Kuur Therapeutics, Inc., the leading developer of off-the-shelf CAR-NKT cell immunotherapies for the treatment of solid and hematological malignancies.